✦ LIBER ✦

A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

✍ Scribed by Ferenci, Peter; Aires, Rodrigo; Ancuta, Ioan; Arohnson, Andrew; Cheinquer, Hugo; Delic, Dragan; Gschwantler, Michael; Larrey, Dominique; Tallarico, Ludovico; Schmitz, Manuela; Tatsch, Fernando; Ouzan, Denis

Book ID: 127171634
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 299 KB
Volume: 34
Category: Article
ISSN: 0106-9543
DOI: 10.1111/liv.12439

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of sustained virological resp

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

✍ Foster, Graham R.; Fried, Michael W.; Hadziyannis, Stephanos J.; Messinger, Diet 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 392 KB

Predicting sustained virological respons

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin

✍ Peter Ferenci; Michael W. Fried; Mitchell L. Shiffman; Coleman I. Smith; George 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Predicting sustained virological respons

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin

✍ Eric Snoeck; Janet R. Wade; Frank Duff; Matthew Lamb; Karin Jorga 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

1108 SELECTION OF HCV GENOTYPE 1 PATIENT

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

✍ Ferenci, P.; Aires, R.; Ancuta, I.; Arohnson, A.; Cheinquer, H.; Delic, D.; Gsch 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

995 A dynamic model to predict sustained

995 A dynamic model to predict sustained virological response to combination peginterferon alfa-2A (40KD) (PEGASYS(®)) and ribavirin (COPEGUS(®)) therapy in patients with chronic hepatitis C

✍ FERENCI, P; FRIED, M; CHANEAC, M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

828 TREATMENT WITH PEGINTERFERON ALFA-2A

828 TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN OLDER HCV GENOTYPE 1 PATIENTS WITH POSITIVE PROGNOSTIC FACTORS LEADS TO HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE

✍ K.R. Reddy; D. Messinger; M. Popescu; S.J. Hadziyannis 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB